Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction

被引:102
作者
De Luca, Giuseppe [1 ]
Ernst, Nicolette [1 ]
van't Hof, Arnoud W. J. [1 ]
Ottervanger, Jan Paul [1 ]
Hoorntje, Jan C. A. [1 ]
Gosselink, A. T. Marcel [1 ]
Dambrink, Jan-Henk E. [1 ]
de Boer, Menko-Jan [1 ]
Suryapranata, Harry [1 ]
机构
[1] Hosp Weezenlanden, ISALA Klin, Dept Cardiol, NL-8011 JW Zwolle, Netherlands
关键词
D O I
10.1016/j.ahj.2005.06.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Recurrent infarction. after fibrinolytic therapy has been shown to be associated with increased mortality. The aim of this study was to analyze predictors and outcome of reinfarction in a consecutive series of patients undergoing primary angioplasty. Methods Our population is represented by a total of 1955 patients with ST-segment elevation myocardial infarction treated by primary angioplasty between 1997 to 2002. All clinical, angiographic, and follow-up data were prospectively collected. Early reinfarction was defined when two clinical criteria were satisfied within 30 days after the procedure: (1) recurrent ischemic symptoms for > 15 minutes after resolution of symptoms from initial MI; (2) new ST-T-wave changes or new Q waves; (3) reelevation in creatine kinase (CK) or CK-MB to higher levels than normal (or by another 20% if already higher than normal). Results Early reinfarction was observed in 75 (3.8%) patients. At multivariate analysis, advanced Killip class (P =.002), poor preprocedural. TIMI flow (P =.014), administration of IIb-IIIa inhibitors (P =.02), and diabetes (P =.038) were independent predictors of 30-day reinfarction. A total of 107 (5.6%) patients had died. Early reinfarction was associated with a significantly higher mortality (22.7% vs 4.9%, P <.001), even after adjustment for confounding factors (blood pressure, diabetes, Killip class, preprocedural TIMI flow, coronary stenting, multivessel disease, anterior infarct location, preprocedural stenosis, and administration of IIb-IIIa inhibitors) (HR 3.32, 95% CI 1.88-5.84, P <.0001). Conclusions This study showed that, among patients undergoing primary angioplasty for ST-segment elevation myocardial infarction, advanced Killip class at presentation, poor preprocedural TIMI flow, the use of IIb-IIIa inhibitors, and diabetes are independently associated with 30-day reinfarction. Early reinfarction is an independent predictor of 1-year mortality.
引用
收藏
页码:1256 / 1259
页数:4
相关论文
共 21 条
  • [1] A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction
    Antoniucci, D
    Rodriguez, A
    Hempel, A
    Valenti, R
    Migliorini, A
    Vigo, F
    Parodi, G
    Fernandez-Pereira, C
    Moschi, G
    Bartorelli, A
    Santoro, GM
    Bolognese, L
    Colombo, A
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (11) : 1879 - 1885
  • [2] Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation
    Antoniucci, D
    Valenti, R
    Migliorini, A
    Moschi, G
    Trapani, M
    Dovellini, EV
    Bolognese, L
    Santoro, GM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (04) : 353 - 357
  • [3] Clopidogrel versus ticlopidine after intracoronary stent placement
    Berger, PB
    Bell, MR
    Rihal, CS
    Ting, H
    Barsness, G
    Garratt, K
    Bellot, V
    Mathew, V
    Melby, S
    Hammes, L
    Grill, D
    Holmes, DR
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (07) : 1891 - 1894
  • [4] Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
    Bertrand, ME
    Rupprecht, HJ
    Urban, P
    Gershlick, AH
    [J]. CIRCULATION, 2000, 102 (06) : 624 - 629
  • [5] Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction
    Chan, AW
    Chew, DP
    Bhatt, DL
    Moliterno, DJ
    Topol, EJ
    Ellis, SG
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02) : 132 - 136
  • [6] Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study
    Davis, TME
    Fortun, P
    Mulder, J
    Davis, WA
    Bruce, DG
    [J]. DIABETOLOGIA, 2004, 47 (03) : 395 - 399
  • [7] Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction - A meta-analysis of randomized trials
    De Luca, G
    Suryapranata, H
    Stone, GW
    Antoniucci, D
    Tcheng, JE
    Neumann, FJ
    Van de Werf, F
    Antman, EM
    Topol, EJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (14): : 1759 - 1765
  • [8] Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty
    De Luca, G
    Ernst, N
    Zijlstra, F
    van't Hof, AWJ
    Hoorntje, JCA
    Dambrink, JHE
    Gosslink, ATM
    de Boer, MJ
    Suryapranata, H
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (08) : 1363 - 1367
  • [9] Prevalence of silent myocardial ischemia in persons with diabetes mellitus or impaired glucose tolerance and association of hemoglobin A1c with prevalence of silent myocardial ischemia
    Deluca, AJ
    Saulle, LN
    Aronow, WS
    Ravipati, G
    Weiss, MB
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (12) : 1472 - 1474
  • [10] Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results front the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction [MITRA], and the Myocardial Infarction Registry [MIR])
    Dönges, K
    Schiele, R
    Gitt, A
    Wienbergen, H
    Schneider, S
    Zahn, R
    Grube, R
    Baumgartel, B
    Glunz, HG
    Senges, J
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (09) : 1039 - 1044